Anti-angiogenic treatment of human cancer: Pitfalls and promises

International Journal of Cancer

Volumn 86, Issue 6, 2000, Pages 870-873

  Westphal, Johan R ^a   Ruiter, Dirk J ^a   De Waal, Robert M W ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR;

ANGIOGENESIS; ARTICLE; CANCER; HUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR BLOOD FLOW;

EID: 0034660015     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(20000615)86:6<870::aid-ijc17>3.0.co;2-1     Document Type: Article

References (68)

1. ARORA, N., MASOOD, R., ZHENG, T., CAI, J., SMITH, D.L. and GILL, P.S., Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res., 59, 183-188 (1999).
2. BERGERS, G., JAVAHERIAN, K., LO, K.-M., FOLKMAN, J. and HANAHAN, D., Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science, 284, 808-812 (1999).
3. BERTOLINI, F., PAOLUCCI, M., PECCATORI, F., CINIERI, S., AGAZZI, A., FERRUCCI, P.F., COCOROCCHIO, E., GOLDHIRSCH, A. and MARTINELLI, G., Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Brit. J. Hematol., 106, 504-509 (1999).
4. BOEHM, T., FOLKMAN, J., BROWDER, T. and O'REILLY, M.S., Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond.), 390, 404-407 (1998a).
5. BOEHM, T., O'REILLY, M.S., KEOUGH, K.M., SHILOACH, J., SHAPIRO, R. and FOLKMAN, J., Zinc-binding of endostatin is essential for its antiangiogenic activity. Biochem. biophys. Res. Comm., 252, 190-194 (1998b).
6. BROOKS, P.C., Role of integrins in angiogenesis. Europ. J. Cancer, 32A, 2423-2429 (1996).
7. BROOKS, P.C., STROMBLAD, S., KLEMKE, R., VISSCHER, D., SARKAR, F.H. and CHERESH, D.A., Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human. J. clin. Invest., 96, 1815-1822 (1995).
8. BURROWS, F.J. and THORPE, P.E., Eradication of large solid tumos in mice with an iminunotoxin directed against tumor vasculature. Proc. nat. Acad. Sci. (Wash.), 90, 8996-9000 (1993).
9. BUSSOLINO, F., ALBINI, A., CAMUSSI, G., PRESTA, M., VIGLIETTO, G., ZICHE, M. and PERSICO. G., Role of soluble mediators in angiogenesis. Europ. J. Cancer, 34A, 2401-2412 (1997).
10. CAO, Y., JI, R.-W., DAVIDSON, D., SCHALLER, J., MARTI, D., SÖHNDEL, S., MCCANCE, S.G. , O'REILLY, M.S., LLINÁS, M. and FOLKMAN, J., Kringle domains of human angiostatin. J. biol. Chem., 271, 29461-29467 (1996).
11. CARRELL, R.W., How serpins are shaping up. Science, 285, 1861-1863 (1999).
12. CLEMENT, B., MUSSO, O., LIETARD, J. and THERET, N., Homeostatic control of angiogenesis: A newly identified function of the liver? Hepatology, 29, 621-623 (1999).
13. CRYSTAL, R.G., The body as a manufacturer of endostatin. Nature (Biotechnol.), 17, 336-337 (1999).
14. D'AMATO, R.J., LOUGHNAN, M.S., FLYNN, E. and FOLKMAN, J., Thalidomide is an inhibitor of angiogenesis. Proc. nat. Acad. Sci. (Wash.), 91, 4082-4085 (1994).
15. DAMERON, K.M., VOLPERT, O.V., TAINSKY, M.A. and BOUCK, N., Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science, 265, 1582-1585 (1994).
16. DHANABAL, M., RAMCHANDRAN, R., VOLK, R., STILLMAN, I.E., LOMBARDO, M., IRUELA-ARISPE, M.L., SIMONS, M. and SUKHATME, V.P., Endostatin: Yeast production, mutants, and antitumor effect in renal cell carcinoma. Cancer Res., 59, 189-197 (1999).
17. DING, Y.H., JAVAHERIAN, K., LO, K.M., CHOPRA, R., BOEHM, T., LANCIOTTI, J., HARRIS, B.A., LI. Y., SHAPIRO, R., HOHENESTER, E., TIMPL, R., FOLKMAN, J. and WILEY, D.C., Zinc-dependent dimers observed in crystals of human endostatin. Proc. Nat. Acad. Sci. (Wash.), 95, 10443-10448 (1998).
18. DONG, Z., KUMAR, R., YANG, X. and FIDLER, I.J., Macrophage-derived inetalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell, 88, 801-810 (1997).
19. DVORAK, H.F., BROWN, L.F., DETMAR, M. and DVORAK, A.M., Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Amer. J. Pathol., 146, 1029-1039 (1995).
20. FALCONE, D.J., KHAN, K.M.F., LAYNE, T. and FERNANDES, L., Macrophage formation of angiostatin during inflammation - A byproduct of the activation of plasminogen. J. biol. Chem., 273, 31480-31485 (1998).
21. FIDLER, I.J. and ELLIS, L.M., The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell, 79, 185-188 (1994).
22. FOLKMAN, J., Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med., 285, 1182-1186 (1971).
23. FOLKMAN, J., What is the evidence that tumors are angiogenesis dependent? J. nat. Cancer. Inst., 82, 1-3 (1990).
24. FOLKMAN, J., Angiogenesis inhibitors generated by tumors. Mol. Med., 1, 120-122 (1995a).
25. FOLKMAN, J., Clinical applications of research on angiogenesis. N. Engl. J. Med., 333, 1757-1763 (1995b).
26. FOLKMAN, J., New perspectives in clinical oncology from angiogenesis research. Europ. J. Cancer, 32A, 2534-2539 (1996).
27. FOLKMAN, J. and D'AMORE, P.A., Blood vessel formation: What is its molecular basis? Cell, 87, 1153-1155 (1996).
28. GATELY, S., TWARDOWSKI, P., STACK, M.S., PATRICK, M., BOGGIO, L., CUNDIFF, D.L., SCHNAPER, H.W., MADISON, L., VOLPERT, O.V., BOUCK, N., ENGHILD, J., KWAAN, H.C. and SOFF, G.A., Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res., 56, 4887-4890 (1996).
29. GORRIN RIVAS, M.J., ARII, S., FURUTANI, M., HARADA, T., MIZUMOTO, M., NISHIYAMA, H., FUJITA, J. and IMAMURA, M., Expression of human macrophage metalloelastase gene in hepatocellular carcinoma: Correlation with angiostatin generation and its clinical significance. Hepatology, 28, 986-993 (1998).
30. GORSKI, D.H., MAUCERI, H.J., SALLOUM, R.M., GATELY, S., HELLMAN, S., BECKETT, M.A., SUKHATME, V.P., SOFF, G.A., KUFE, D.W. and WEICHSELBAUM, R.R., Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res., 58, 5686-5689 (1998).
31. HANAHAN, D., Signaling vascular morphogenesis and maintenance. Science, 277, 48-50 (1997).
32. HARRIS, A.L., Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy. Rec. Res. Cancer Res., 152, 341-352 (1998).
33. HEFLER, L., TEMPFER, C., KAINZ, C. and OBERMAIR, A., Serum concentrations of endostatin in patients with vulvar cancer. Gynecol. Oncol., 74, 151-152 (1999).
34. HUANG, X., MOLEMA, G., KING, S., WATKINS, L., EDGINGTON, T.S. and THORPE, P.E., Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science, 275, 547-550 (1997).
35. JAIN, R.K., Transport of molecules in the tumor interstitium: A review. Cancer Res., 47, 3039-3051 (1987).
36. JOE, Y.A., HONG, Y.K., CHUNG, D.S., YANG, Y.J., KANG, J.K., LEE, Y.S., CHANG, S.I., YOU, W.K., LEE, H. and CHUNG, S.I. Inhibition of human malignant glioma growth in vivo by human recombinant plasminogen kringles 1-3. Int. J. Cancer, 82, 694-699 (1999).
37. JOHN, H., PREISSNER, K.T., FORSSMANN, W.G. and STANDKER, L., Novel glycosylated forms of human plasma endostatin and circulating endostatin-related fragments of collagen XV. Biochemistry, 38, 10217-10224 (1999).
38. KERBEL, R.S., A cancer therapy resistant to resistance. Nature (Lond.), 390, 335-336 (1997).
39. KLAGSBRUN, M., Angiogenesis and cancer. AACR special conference in cancer research. Cancer Res., 59, 487-490 (1999).
40. LEE SIM, B.K., O'REILLY, M.S., LIANG, H., FORTIER, A.H., HE, W., MADSEN, J.W., LAPCEVICH, R. and NACY, C.A., A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res., 57, 1329-1334 (1997).
41. LEENDERS, W.P.J., Targetting VEGF in anti-angiogenic and anti-tumour therapy: Where are we now? Int. J. exp. Pathol., 79, 339-346 (1998).
42. LUNEN, H.R., UGWU, F., BINI, A. and COLLEN, D., Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry, 37, 4699-4702 (1998).
43. LUCAS, R., HOLMGREN, L., GARCIA, I., JIMENEZ, B., MANDRIOTA, S.J., BORLAT, F., SIM, B.K., Wu, Z., GRAU, G.E., SHING, Y., SOFF, G.A., BOUCK, N. and PEPPER, M.S., Multiple forms of angiostalin induce apoptosis in endothelial cells. Blood, 92, 4730-4741 (1998).
44. MALCERI, H.J. and 13 OTHERS, Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature (Lond.), 394, 287-291 (1998).
45. OLSON, T.A., MOHANRAJ, D., ROY, S. and RAMAKRISHNAN, S., Targetting the tumor vasculature: Inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate. Int. J. Cancer, 73, 865-870 (1997).
46. O'MAHONY, C.A., SEIDEL, A., ALBO, D., CHANG, H., TUSZYNSKI, G.P. and BERGER, D.H., Angiostatin generation by human pancreatic cancer. J. surg. Res., 77, 55-58 (1998).
47. O'REILLY, M.S., HOLMGREN, L., SHING, Y., CHEN, C., ROSENTHAL, R.A., MOSES, M., LANE, W.S., CAO, Y., SAGE, E.H. and FOLKMAN, J., Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell, 79, 315-328 (1994).
48. O'REILLY, M.S., HOLMGREN, L., CHEN, C. and FOLKMAN, J., Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature (Med.), 2, 689-692 (1996).
49. O'REILLY, M.S., BOEHM, T., SHING, Y., FUKAI, N., VASIOS, G., LANE, W.S., FLYNN, E., BIRKHEAD, J.R., OLSEN, B.R. and FOLKMAN, J., Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277-285 (1997).
50. O'REILLY, M.S., PIRIE, S.S., LANE, W.S. and FOLKMAN, J., Antiangiogenic activity of the cleaved conformation of the serpin antithrombin. Science, 285, 1926-1928 (1999a).
51. O'REILLY, M.S., WIEDERSCHAIN, D., STETLER STEVENSON, W.O., FOLKMAN, J. and MOSES, M.A., Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J. biol. Chem., 274, 29568-29571 (1999b).
52. PARANGI, S., O'REILLY, M.S., CHRISTOFORI, G., HOLMGREN, L., GROSVELD, J., FOLKMAN, J. and HANAHAN, D., Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc. nat. Acad. Sci. (Wash.), 93, 2002-2007 (1996).
53. PASQUALINI, R., KOIVUNEN, E. and RUOSLAHTI, E., Alpha v integrins as receptors for tumor targeting by circulating ligands. Nature (Biotechnol.), 15, 542-546 (1997).
54. PATTERSON, B.C. and SANG, Q.A., Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/typeIV collagenase (MMP-9). J. biol. Chem., 272, 28823-28825 (1997).
55. PINTUCCI, G., BIKFALVI, A., KLEIN, S. and RIFKIN, D.B., Angiogenesis and the fibrinolytic system. Semin. Thrombosis Hemostasis, 22, 517-524 (1996).
56. PÖTGENS, A.J.G., WESTPHAL, J.R., DE WAAL, R.M.W. and RUITER, D.J., The role of vascular permeability factor and basic fibroblast growth factor in tumor angiogenesis. Biol. Chem. Hoppe-Seyler, 376, 57-70 (1995).
57. RAMAKRISHNAN, S., OLSON, T.A., BAUTCH, V.L. and MOHANRAJ, D., Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/ flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res., 56, 1324-1330 (1996).
58. RAN, S., GAO, B., DUFFY, S., WATKINS, L., ROTE, N. and THORPE, P.E., Infarction of solid Hodgkin's tumors in mice antibody-directed targeting of tissue factor to tumor vasculature. Cancer Res., 58, 4646-4653 (1998).
59. RASMUSSEN, H.S. and MCCANN, P.P., Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on batimastat and marimastat. Pharmacol. Ther., 75, 69-75 (1997).
60. RUOSLAHTI, E., Integrins as signaling molecules and targets for tumor therapy. Kidney Int., 51, 1413-1417 (1997).
61. SANG, Q.X.A., Complex role of matrix metalloproteinases in angiogenesis. Cell Res., 8, 171-177 (1998).
62. SASAKI, A., ALCALDE, R.E., NISHIYAMA, A., LIM, D.D., MESE, H., AKEDO, H. and MATSUMURA, T., Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption. Cancer Res., 58, 462-467 (1998).
63. SCHUPPAN, D., CRAMER, T., BAUER, M., STREFELD, T., HAHN, E.G. and HERBST, H., Hepatocyles as a source of collagen typo XVIII endostatin. Lancet, 352, 879-880 (1998).
64. STÄNDKER, L., SCHRADER, M., KANSE, S.M., JÜRGENS, M., FORSSMANN, W.-G. and PREISSNER, K.T., Isolation and characterization of the circulating form of human endostatin. FEBS Lett., 420, 129-133 (1997).
65. TALBOT, D.C. and BROWN, P.D., Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancer. Europ. J. Cancer, 32A, 2528-2533 (1996).
66. VARNER, J.A. and CHERESH, D.A., Tumor angiogenesis and the role of vascular cell integrin alphavbeta3. Import. Adv. Oncol., 69-87 (1996).
67. YAMAGUCHI, N., ANAND, A.B., LEE., M., SASAKI, T., FUKAI, N., SHAPIRO, R., QUE, I., LOWIK, C., TIMPL, R. and OLSEN, B.R. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J., 18, 4414-4423 (1999).
68. ZETTER, B.R., Angiogenesis and tumor metastasis. Ann. Rev. Med., 49, 407-424 (1998).